We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -3.67% | 2.10 | 2.01 | 2.10 | 2.25 | 2.10 | 2.20 | 2,011,776 | 15:32:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.84 | 7M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/12/2017 09:45 | There have been pauses and consolidation at 80p 100p and 130p and all have been utterly smashed before the move higher. This feels like another pause at 170p before the inevitable next step up. I fancy the next leg to go straight through 200p without a backward glance. | qazwsxedc69 | |
12/12/2017 09:21 | Few more buys should tick up again hopefully | aussieb3 | |
12/12/2017 09:21 | Mostly buys but no share price rise, looks like a few sell orders coming in, steady rises here better than spikes, which are sold into, a few new aliases appearing, the herd has arrived! Buy..hold and forget about these until early 2018 | ny boy | |
12/12/2017 09:12 | And if anyone wants to nominate me for the 'stating the bleeding obvious' award - then I would be happy to accept it (I have a speech already prepared) | hamhamham1 | |
12/12/2017 08:55 | IMHO. This share is only going to go one way (up) for the next month or two. Its more a question of what angle the climb takes. There may be the odd RNS to inform last drug administered and last patient readings taken. Then the big date is when the results data is released. But as I said, until then its upwards as anticipations and expectations mount. DYOR. | hamhamham1 | |
12/12/2017 08:43 | valuations given by brokers usually are very conservative | divinessence | |
12/12/2017 08:40 | I don't reckon that QS I reckon that valuation is very conservative :-) | spawny100 | |
12/12/2017 08:39 | Yes a few new names popping up amongst regulars. Not to worry just hang on to your shares if they try to shake weak holders out imo | spawny100 | |
12/12/2017 08:37 | So £8.79p you reckon if successful Phase III? with bid premium on top maybe if a major wanted to take them out? DYOR etc....happy to play that numbers game! | qs99 | |
12/12/2017 08:35 | Feels like the herd are coming...not sure if that's a good thing though but given market cap here the results and institutions will be the price shifters here | costapacket | |
12/12/2017 08:32 | This time next year Rodney!:) | uncleoswald | |
12/12/2017 08:29 | Yep that's how I read it HK | spawny100 | |
12/12/2017 08:29 | Correct Spawny They are suggesting it will be 443p on successful phase III.....PLUS 50p PLUS 386p.In other words 879p.Boom time | herschel k | |
12/12/2017 08:17 | well people said that around the £1.30 mark! | qs99 | |
12/12/2017 08:13 | I think a few people are getting ahead of themselves. Think it will be a bit up and down around this mark till the results come now. | ourbr3tt0 | |
12/12/2017 07:52 | come jan/feb we will be above £5 | falia | |
12/12/2017 07:50 | That 386p is only the value of the milestone payments per share if I read it correctly i.e ON TOP of the valuation | spawny100 | |
12/12/2017 07:44 | Fincap says 386p Magic bullet with butterfly wings? 386p Boom boom 💥 | vatpaul | |
12/12/2017 07:35 | 200 today lol. Ny boy your being outramped | davr0s | |
12/12/2017 07:33 | vatpaul Member since: 21 Nov 2017 Just wondering when you started buying these? | ny boy | |
12/12/2017 07:26 | Boomtime here. VAL as well today and poss AOR. Bio is place to be right now. | spawny100 | |
12/12/2017 07:15 | Immupharma (IMM) is a drug discovery company whose lead product Lupuzor, is in Phase III trials for the treatment of Systemic Lupus Erythematous (SLE). Previous IIb trial demonstrated both efficacy and safety through novel immune system modulation that offers benefits to the only approved treatment, a monoclonal antibody (mAb) called Benlysta with £400m annual sales. Phase III pivotal study readout (n=200) expected Q1-18 (finnCap est. approval of 63%) follows on from Lupuzor being given Special Protocol Assessment (SPA) status by the FDA with existing global patent protection until 2032. Blockbuster status (sales >$1bn) could be achieved within 8 years and historical licence deal (Cephalon, 2009) suggestive of licence/partner agreement potential. Unusual upside potential from binary readout leads us to initiate coverage with a Buy recommendation and 237p price target (increasing 87% on +ve Phase III, which excludes the value of potential upfront (c.50p) and milestone payments that could amount to c£500m or 386p per share). Will be over 200 today for sure | vatpaul | |
12/12/2017 06:27 | "To be considered a responder a patient has to have an improvement in at least 6 of the 24 measures."I imagine improvement between many of the measures are highly correlated. They will know the drop out rate. | wigwammer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions